 |
Pharmaceutical Research & Development
|
|
R&D Facts
|
|
|
|
Executive Vice President, Chief Scientific Officer and President,
Research and Development
|
Elliott
Sigal, M.D., Ph.D.
|
|
| Major
R&D Facilities: |
Banglor, India
Hopewell, New Jersey
Lawrenceville, New Jersey
Moreton, United Kingdom
New Brunswick, New Jersey
Paris, France
Plainsboro, New Jersey
New Brunswick, New Jersey
Wallingford, Connecticut
Waltham, Massachusetts
Braine-L'Alleud, Belgium
Tokyo, Japan
|
 |
Pharmaceutical R&D Investment:
|
$3.1
billion in 2007
|
|
R&D
Areas:
|
Nearly
40 compounds in development in the following critical disease
areas: cancer,
atherosclerosis/thrombosis, diabetes, obesity, psychiatric
disorders, Alzheimer’s disease, hepatitis, HIV/AIDS, rheumatoid
arthritis and solid organ transplantation.
|
|
Pharmaceutical
R&D
Staff:
|
Approximately
7,000 employees worldwide
|
|
|
|
|
Data
above as reported in the Bristol-Myers Squibb 2007 Annual Report
Alliances
Clinical Trial Disclosure
|
[Top Page] [Search]
[Index] [Contact] [Home]
Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.
© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy. |
|
|
|
